目的系统评价钠—葡萄糖协同转运蛋白-2抑制剂(SGLT2i)治疗2型糖尿病的有效性和安全性。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science及中国知网、万方数据知识服务平台上公开发表的SGLT2i治疗2型糖尿病患者有效性...目的系统评价钠—葡萄糖协同转运蛋白-2抑制剂(SGLT2i)治疗2型糖尿病的有效性和安全性。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science及中国知网、万方数据知识服务平台上公开发表的SGLT2i治疗2型糖尿病患者有效性及安全性的随机对照试验(RCTs),文献检索时限从建库至2022年5月1日。对照组给予安慰剂治疗,试验组给予SGLT2i治疗。根据Cochrane偏倚风险评价工具对纳入文献进行质量评价,采用RevMan 5.3软件和Stata软件进行Meta分析。结果最终纳入5篇文献,共包含40205例患者,文献整体质量较高。Meta分析结果显示,与对照组相比,试验组心血管死亡或首次心力衰竭住院风险[HR=0.75,95%CI(0.61,0.92),P=0.005]、首次心力衰竭住院风险[HR=0.70,95%CI(0.60,0.82),P<0.001]显著降低,但2组心血管死亡风险[HR=0.99,95%CI(0.84,1.16),P=0.86]、全因死亡风险[HR=0.92,95%CI(0.83,1.01),P=0.09]、严重不良反应发生率[HR=1.01,95%CI(0.93,1.09),P=0.84]、急性损伤发生率[HR=0.84,95%CI(0.63,1.12),P=0.24]比较差异无统计学意义。Egger检验结果显示,报道心血管死亡或首次心力衰竭住院风险、首次心力衰竭住院风险的文献无明显发表偏倚(P值分别为0.22、0.37)。结论基于现有证据表明,SGLT2i可降低2型糖尿病患者心血管死亡或首次心力衰竭住院综合风险和首次心力衰竭住院风险,且无严重不良反应和急性肾损伤发生。展开更多
SGLT-2 (钠–葡萄糖协同转运蛋白2)抑制剂是一种新型降糖药,它作用于肾脏,能够降低肾脏重新吸收葡萄糖的能力,促使尿糖排泄量增加,最终达到降低血糖水平的效果。近年来,SGLT-2被发现不仅具有降糖的作用,还可以通过抑制葡萄糖代谢、抑制...SGLT-2 (钠–葡萄糖协同转运蛋白2)抑制剂是一种新型降糖药,它作用于肾脏,能够降低肾脏重新吸收葡萄糖的能力,促使尿糖排泄量增加,最终达到降低血糖水平的效果。近年来,SGLT-2被发现不仅具有降糖的作用,还可以通过抑制葡萄糖代谢、抑制血管生成、影响免疫微环境等多个机制起到抗肿瘤的作用。目前,SGLT-2抑制剂在肺癌中的作用的研究仍处于初步阶段,这篇综述系统地阐述了SGLT-2抑制剂在肺癌中的研究进展,希望能为未来SGLT-2抑制剂在肺癌中的应用提供参考。SGLT-2 (sodium-glucose co-transporter protein-2) inhibitor is a new type of hypoglycemic drug, which acts on the kidneys and can reduce the kidney’s ability to reabsorb glucose, prompting an increase in urinary glucose excretion, and ultimately achieving the effect of lowering blood glucose levels. In recent years, SGLT-2 has been found to not only have a hypoglycemic effect, but also play an anti-tumor role by inhibiting glucose metabolism, inhibiting angiogenesis, affecting the immune microenvironment and other mechanisms. At present, the research on the role of SGLT-2 inhibitors in lung cancer is still in the preliminary stage, and this review systematically describes the research progress of SGLT-2 inhibitors in lung cancer, hoping to provide a reference for the future application of SGLT-2 inhibitors in lung cancer.展开更多
心脏重塑是心脏在持续性压力、代谢等刺激下发生的适应性形态结构变化过程,其中病理性心脏重塑是心血管不良事件独立危险因素。新型降糖药物钠–葡萄糖协同转运蛋白-2 (sodium-glucose cotransporter 2, SGLT2)抑制剂除了能够降低容量...心脏重塑是心脏在持续性压力、代谢等刺激下发生的适应性形态结构变化过程,其中病理性心脏重塑是心血管不良事件独立危险因素。新型降糖药物钠–葡萄糖协同转运蛋白-2 (sodium-glucose cotransporter 2, SGLT2)抑制剂除了能够降低容量负荷、减少心血管死亡及住院风险外,还展现出改善心脏结构和功能、逆转心脏重构的潜力。本文旨在对SGLT2抑制剂在改善心脏重塑方面的研究进展进行综述。Cardiac remodeling, a process of adaptive morphological and structural alterations in the heart triggered by sustained stress, metabolic, and other stimuli, among which pathological cardiac remodeling serves as an independent predictor of adverse cardiovascular outcomes. Recently, novel hypoglycemic agents, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, have emerged as potential therapeutics that not only alleviate volume overload but also reduce the risk of cardiovascular mortality and hospitalization. Additionally, these agents exhibit promising effects in improving cardiac structure and function, as well as reversing pathological cardiac remodeling. This article aims to comprehensively review the progress made in investigating the therapeutic benefits of SGLT2 inhibitors in ameliorating cardiac remodeling.展开更多
钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为一种新型口服降糖药,对2型糖尿病或非糖尿病患者都表现出良好的心肾保护作用,并可改善慢性肾脏病患者的心肾结局。虽然目前临床试验已将纳入人群的估算肾小球滤过率(eGFR)扩展至更低水平,但仍...钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为一种新型口服降糖药,对2型糖尿病或非糖尿病患者都表现出良好的心肾保护作用,并可改善慢性肾脏病患者的心肾结局。虽然目前临床试验已将纳入人群的估算肾小球滤过率(eGFR)扩展至更低水平,但仍排除了eGFR<20 mL/(min·1.73 m 2)的患者,SGLT2i的心肾保护作用能否延续至维持性透析期是临床关注的重点。此外,SGLT2i的抗炎和抗纤维化作用可能对腹膜透析(PD)患者维持腹膜功能有益。因此,SGLT2i在PD患者中的应用值得进一步探索。展开更多
文摘目的系统评价钠—葡萄糖协同转运蛋白-2抑制剂(SGLT2i)治疗2型糖尿病的有效性和安全性。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science及中国知网、万方数据知识服务平台上公开发表的SGLT2i治疗2型糖尿病患者有效性及安全性的随机对照试验(RCTs),文献检索时限从建库至2022年5月1日。对照组给予安慰剂治疗,试验组给予SGLT2i治疗。根据Cochrane偏倚风险评价工具对纳入文献进行质量评价,采用RevMan 5.3软件和Stata软件进行Meta分析。结果最终纳入5篇文献,共包含40205例患者,文献整体质量较高。Meta分析结果显示,与对照组相比,试验组心血管死亡或首次心力衰竭住院风险[HR=0.75,95%CI(0.61,0.92),P=0.005]、首次心力衰竭住院风险[HR=0.70,95%CI(0.60,0.82),P<0.001]显著降低,但2组心血管死亡风险[HR=0.99,95%CI(0.84,1.16),P=0.86]、全因死亡风险[HR=0.92,95%CI(0.83,1.01),P=0.09]、严重不良反应发生率[HR=1.01,95%CI(0.93,1.09),P=0.84]、急性损伤发生率[HR=0.84,95%CI(0.63,1.12),P=0.24]比较差异无统计学意义。Egger检验结果显示,报道心血管死亡或首次心力衰竭住院风险、首次心力衰竭住院风险的文献无明显发表偏倚(P值分别为0.22、0.37)。结论基于现有证据表明,SGLT2i可降低2型糖尿病患者心血管死亡或首次心力衰竭住院综合风险和首次心力衰竭住院风险,且无严重不良反应和急性肾损伤发生。
文摘SGLT-2 (钠–葡萄糖协同转运蛋白2)抑制剂是一种新型降糖药,它作用于肾脏,能够降低肾脏重新吸收葡萄糖的能力,促使尿糖排泄量增加,最终达到降低血糖水平的效果。近年来,SGLT-2被发现不仅具有降糖的作用,还可以通过抑制葡萄糖代谢、抑制血管生成、影响免疫微环境等多个机制起到抗肿瘤的作用。目前,SGLT-2抑制剂在肺癌中的作用的研究仍处于初步阶段,这篇综述系统地阐述了SGLT-2抑制剂在肺癌中的研究进展,希望能为未来SGLT-2抑制剂在肺癌中的应用提供参考。SGLT-2 (sodium-glucose co-transporter protein-2) inhibitor is a new type of hypoglycemic drug, which acts on the kidneys and can reduce the kidney’s ability to reabsorb glucose, prompting an increase in urinary glucose excretion, and ultimately achieving the effect of lowering blood glucose levels. In recent years, SGLT-2 has been found to not only have a hypoglycemic effect, but also play an anti-tumor role by inhibiting glucose metabolism, inhibiting angiogenesis, affecting the immune microenvironment and other mechanisms. At present, the research on the role of SGLT-2 inhibitors in lung cancer is still in the preliminary stage, and this review systematically describes the research progress of SGLT-2 inhibitors in lung cancer, hoping to provide a reference for the future application of SGLT-2 inhibitors in lung cancer.
文摘心脏重塑是心脏在持续性压力、代谢等刺激下发生的适应性形态结构变化过程,其中病理性心脏重塑是心血管不良事件独立危险因素。新型降糖药物钠–葡萄糖协同转运蛋白-2 (sodium-glucose cotransporter 2, SGLT2)抑制剂除了能够降低容量负荷、减少心血管死亡及住院风险外,还展现出改善心脏结构和功能、逆转心脏重构的潜力。本文旨在对SGLT2抑制剂在改善心脏重塑方面的研究进展进行综述。Cardiac remodeling, a process of adaptive morphological and structural alterations in the heart triggered by sustained stress, metabolic, and other stimuli, among which pathological cardiac remodeling serves as an independent predictor of adverse cardiovascular outcomes. Recently, novel hypoglycemic agents, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, have emerged as potential therapeutics that not only alleviate volume overload but also reduce the risk of cardiovascular mortality and hospitalization. Additionally, these agents exhibit promising effects in improving cardiac structure and function, as well as reversing pathological cardiac remodeling. This article aims to comprehensively review the progress made in investigating the therapeutic benefits of SGLT2 inhibitors in ameliorating cardiac remodeling.
文摘钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为一种新型口服降糖药,对2型糖尿病或非糖尿病患者都表现出良好的心肾保护作用,并可改善慢性肾脏病患者的心肾结局。虽然目前临床试验已将纳入人群的估算肾小球滤过率(eGFR)扩展至更低水平,但仍排除了eGFR<20 mL/(min·1.73 m 2)的患者,SGLT2i的心肾保护作用能否延续至维持性透析期是临床关注的重点。此外,SGLT2i的抗炎和抗纤维化作用可能对腹膜透析(PD)患者维持腹膜功能有益。因此,SGLT2i在PD患者中的应用值得进一步探索。
